{"DataElement":{"publicId":"6384148","version":"1","preferredName":"New Lesion Appearance iRECIST Type","preferredDefinition":"The classification of a new lesion based upon a common qualities based on Immune Response Evaluation Criteria in Solid Tumors (iRECIST) criteria.","longName":"NEW_LES_iRECIST_TP","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"2188736","version":"1","preferredName":"New Lesion Appearance","preferredDefinition":"information related to the appearance of a new lesion.","longName":"NEW_LES_APR","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2206397","version":"1","preferredName":"New Lesion","preferredDefinition":"New; having no previous example or precedent or parallel.:(LEE-zhun) An area of abnormal tissue change.","longName":"C25586:C3824","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"New","conceptCode":"C25586","definition":"Having no previous example or precedent or parallel; of a kind not seen before.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F3D2-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177628","version":"1","preferredName":"Appearance","preferredDefinition":"Appearance; the outward or visible aspect of a person or thing.","longName":"Appearance","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Appearance","conceptCode":"C25377","definition":"The outward or visible aspect of a person or thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-517B-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E5513DAC-3745-3D42-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-30","modifiedBy":"KNABLEJ","dateModified":"2017-08-31","changeDescription":"8/30/17 jk transferred context and added CSI, registration status per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6384125","version":"1","preferredName":"iRECIST New Lesion Type","preferredDefinition":"A modification of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for use as a standard approach to solid tumor measurements and definitions for objective change in tumor size in cancer clinical trials in which an immunotherapy is used._The identification of a lesion which has not been previously seen or characterized._Something distinguishable as an identifiable class based on common qualities.","longName":"iRECIST_NEW_LES_TP","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"5682943","version":"1","preferredName":"No","longName":"5682943","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9AC2-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"DWARZEL","dateModified":"2018-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C869DF-45F2-31B8-E053-F662850A9B9E","beginDate":"2018-08-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"Yes, first new lesion","valueDescription":"First New Lesion Identification","ValueMeaning":{"publicId":"6384127","version":"1","preferredName":"First New Lesion Identification","longName":"6384127","preferredDefinition":"Preceding all others in time or space or degree.: The identification of a lesion which has not been previously seen or characterized.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"New Lesion Identification","conceptCode":"C94522","definition":"The identification of a lesion which has not been previously seen or characterized.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C7FF24-1FC8-3587-E053-F662850A706E","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C869DF-4607-31B8-E053-F662850A9B9E","beginDate":"2018-08-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"Yes, subsequent new lesion","valueDescription":"Next New Lesion Identification","ValueMeaning":{"publicId":"6384126","version":"1","preferredName":"Next New Lesion Identification","longName":"6384126","preferredDefinition":"Subsequent; immediately following in time or order.: The identification of a lesion which has not been previously seen or characterized.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Next","conceptCode":"C53286","definition":"Subsequent; immediately following in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"New Lesion Identification","conceptCode":"C94522","definition":"The identification of a lesion which has not been previously seen or characterized.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C7FF24-1FA2-3587-E053-F662850A706E","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C869DF-461B-31B8-E053-F662850A9B9E","beginDate":"2018-08-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6384124","version":"1","preferredName":"Immune-Modified Response Evaluation Criteria in Solid Tumors New Lesion Identification Type","preferredDefinition":"A modification of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for use as a standard approach to solid tumor measurements and definitions for objective change in tumor size in cancer clinical trials in which an immunotherapy is used.:The identification of a lesion which has not been previously seen or characterized.:Something distinguishable as an identifiable class based on common qualities.","longName":"C136711:C94522:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Modified Response Evaluation Criteria in Solid Tumors","conceptCode":"C136711","definition":"A modification of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for use as a standard approach to solid tumor measurements and definitions for objective change in tumor size in cancer clinical trials in which an immunotherapy is used.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"New Lesion Identification","conceptCode":"C94522","definition":"The identification of a lesion which has not been previously seen or characterized.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C7FF24-1F79-3587-E053-F662850A706E","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"iRECIST:  Immune Response Evaluation Criteria in Solid Tumours (RECIST)-2017","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"72C7FF24-1F8A-3587-E053-F662850A706E","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-08-06","modifiedBy":"KNABLEJ","dateModified":"2018-10-07","changeDescription":"10/7/18 jk Released per Fall 2018 Content Team review.  8/6/18 jk created for EORTC iRECIST CRF template.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5635324","version":"1","longName":"RECIST","context":"NCI Standards"},{"publicId":"6006601","version":"1","longName":"iRECIST","context":"NCI Standards"}]}],"AlternateNames":[{"name":"2188736v1.0:6384125v1.0","type":"System-Generated","context":"NCI Standards"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"New lesion observed","type":"Preferred Question Text","description":"New lesion observed","url":null,"context":"NCI Standards"},{"name":"iRECIST","type":"Alternate Question Text","description":"Have any new malignant lesions been identified since baseline (i.e. in a previous or current reporting period)?","url":null,"context":"NCI Standards"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Did patient develop new lesions that are measurable since Baseline evaluation?","url":null,"context":"COG"}],"origin":"iRECIST:  Immune Response Evaluation Criteria in Solid Tumours (RECIST)-2017","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"72C7F322-C7C2-255A-E053-F662850A730D","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-08-06","modifiedBy":"LAMEMIL","dateModified":"2020-07-09","changeDescription":"10/7/18 jk Released per Fall 2018 Content Team review.  8/6/18 jk created for EORTC iRECIST follow up form.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}